CD47 and cancer: (130) synthesized pH-responsive M1 exosome nanobioconjugates for cancer treatment, in which azide-modified M1 exosomes conjugated with dibenzo cyclooctyne-modified anti-CD47 and anti-SIRPα antibody (aCD47 and aSIRPα).